Altaris Capital Partners, an investment firm focused exclusively on the healthcare industry, agreed to acquire the Generic Rx Pharmaceuticals unit of Perrigo, an American Irish–registered manufacturer of private label over-the-counter pharmaceuticals, for $1.5bn. "Given our experience in the pharmaceutical sector and track record of corporate carve-out transactions, we believe we are well-positioned to support the Rx business as it becomes a standalone company focused on its mission of developing and marketing affordable pharmaceutical products," Garikai Nyaruwata, Altaris Managing Director.